Who are Ro-Actemra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo to tocilizumab, tocilizumab [RoActemra/Actemra], Tocilizumab plus methotrexate, Tocilizumab(400mg), CT-P47 PFS (tocilizumab), Tocilizumab Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ro-actemra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ro-Actemra — Competitive Intelligence Brief

Ro-Actemra (Ro-Actemra) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 receptor antagonist. Area: Immunology.

marketed IL-6 receptor antagonist IL-6R (Interleukin-6 receptor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Ro-Actemra (Ro-Actemra) — Medical University of Vienna. Ro-Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ro-Actemra TARGET	Ro-Actemra	Medical University of Vienna	marketed	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
Placebo to tocilizumab	Placebo to tocilizumab	Hoffmann-La Roche	marketed	IL-6 receptor antagonist	IL-6 receptor (IL-6R)
tocilizumab [RoActemra/Actemra]	tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Tocilizumab plus methotrexate	Tocilizumab plus methotrexate	SURPRISE Study Group	marketed	IL-6 receptor antagonist + DMARD combination	IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate)
Tocilizumab(400mg)	Tocilizumab(400mg)	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
CT-P47 PFS (tocilizumab)	CT-P47 PFS (tocilizumab)	Celltrion	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)
Tocilizumab Injection	Tocilizumab Injection	Abderrahmane Mami Hospital	phase 3	IL-6 receptor antagonist	IL-6R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 receptor antagonist class)

Hoffmann-La Roche · 4 drugs in this class
Medical University of Vienna · 2 drugs in this class
Bio-Thera Solutions · 1 drug in this class
Biogipuzkoa Health Research Institute · 1 drug in this class
Abderrahmane Mami Hospital · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ro-Actemra — Competitive Intelligence Brief. https://druglandscape.com/ci/ro-actemra. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab